Introduction
A significant number of patients develop epilepsy in adult life, but identification of epileptogenic abnormalities with brain imaging techniques is possible only in a proportion of patients. 1 A large number of patients with refractory epilepsy also have no identifiable structural abnormalities. 2 In recent years, a number of studies have found antibodies directed against neuronal cell surface antigens in patients with epilepsy. These include antibodies against the voltage-gated potassium channel complex (VGKC Abs) and the N-methyl-D-aspartate (NMDA) glutamate receptor. [4] [5] [6] The role of these antibodies in the pathogenesis of epilepsy has not been fully established. Brenner et al. found that VGKC Abs were significantly more likely to occur in patients with focal epilepsy of undetermined cause than in patients with structural/metabolic focal epilepsy. 6 Their study also suggests that the presence of neuronal antibodies in newly diagnosed epilepsy may be associated with a reduced chance of seizure freedom with antiepileptic drug therapy alone. Neurological syndromes associated with antibodies directed against neuronal cell surface antigens often respond to immunotherapy. Therefore, in patients with epilepsy, identification of these antibodies could have important therapeutic implications. Since January 2010, we have tested all adult patients attending our epilepsy service with 'otherwise unexplained' adult onset epilepsy for the presence of VGKC Abs, as well as antibodies to NMDA receptor and glutamate decarboxylase (GAD). We describe a cohort of patients with adult onset cryptogenic focal epilepsy in whom VGKC Abs were detected.
Methods
We reviewed the notes of patients seen between January 2010 and February 2012 in two hospitals in Greater Manchester, England, who had been tested for the presence of VGKC Abs, following presentation with 'unexplained adult onset epilepsy.' This was defined as focal or unclassified epilepsy, with onset in adult life in patients with no history of cerebral insults and no epileptogenic lesions identified on MRI scanning using appropriate imaging protocols. Patients with clearly defined idiopathic generalised epilepsy syndromes and symptomatic epilepsies were not included.
Previous studies have shown VGKC Ab can be found in up to 5% of adult controls at titres between 100 and 400 pM. 5 Patients with VGKC complex Ab titres >400 pM were further investigated by testing for antibodies to leucine-rich glioma inactivated protein 1 (LGI1) and contactin associate protein-like 2 (CASPR2). All testing was performed at the neuroimmunology laboratory at the University of Oxford, using previously described methods of testing for VGKC complex, LGI1 and CASPR2 subunit antibodies. [7] [8] [9] Samples were sent to the laboratory over the study period, and not tested as a single batch. Patients with VGKC Ab >400 pM were offered immunotherapy with corticosteroids, and subsequently azathioprine where felt appropriate by the treating clinician. Details of treatments including immunotherapy, changes in seizure frequency and VGKC Ab titres were recorded at monthly clinical review by one of the authors. Demographic and clinical details, investigation results and response to treatment were collated by review of notes.
Results
144 patients were tested for VGKC Abs between January 2010 and February 2012. This yielded 11 patients (8%) with positive VGKC Ab (>100 pM) of which 6 patients (4.2%) had titres >400 pM. Of the 5 patients with VGKC Ab titres between 100 and 400 pM, one was negative on repeat testing subsequently, and another showed persistent low titre. The remaining three patients became seizure free and did not have the test repeated. The characteristics of patients with VGKC Ab titres >400 pM are summarised in Table 1 Of the 6 patients with VGKC Ab titres >400 pM, 5 were male. The mean age was 52.5 (27-77) years. The mean period between onset of epilepsy and identification of VGKC Abs was 11.5 (0.6-24.0) months. Seizures in all patients were classified as focal seizures and in 4 patients the seizure focus was clinically felt to be the temporal lobe. Semiological features in these patients included rising abdominal sensation, olfactory hallucination, piloerection, dé jà vu, jamais vu, oromasticatory automatisms, and depersonalisation. Two patients experienced generalised tonic clonic seizures (GTCS) in addition to focal seizures. One patient (Patient E) had faciobrachial dystonic seizures (FBDS), recently described in association with LGI1 antibodies, 9 which were detected in this patient. No patient had the clinical syndrome of limbic encephalitis (LE) characterised by amnesia, encephalopathy, personality change or psychosis and seizures. No patient had hyponatraemia at the time of VGKC Ab testing. VGKC Ab titres at initial testing ranged from 180 to 3450 pM. In Patient A (initial VGKC Ab titre 180 pM) the titre rose to >400 pM on repeat testing at a later date. The sera of all 6 patients were tested for the presence of LGI1 and CASPR2 antibodies. Patient E (who presented with FBDS) was positive for LGI1 subunit antibodies. Patient C was positive for CASPR2 antibodies. All other patients were negative for both LGI1 and CASPR2 antibodies.
MRI imaging of the brain was normal in all patients except Patient B, in whom increased signal in the left hippocampus and amygdala was noted at the time of diagnosis and initially attributed to recent seizures. Repeat MRI imaging 12 months later showed volume loss and high signal in the left mesial temporal lobe, consistent with left mesial temporal sclerosis, in spite of immunotherapy and suppression of VGKC Ab titres to undetectable levels, and control of seizures (Fig. 1) .
Four patients had CSF analysis. This was normal in two patients and in two other patients marginally elevated CSF protein levels were seen (0.50-0.53 g/L). CSF analysis for VGKC Ab and oligoclonal bands were negative in all four patients. Patients B, C and E had at least one EEG. No interictal or ictal abnormalities were noted, including during FBDS in Patient E. All patients had whole body CT scan, and two patients had FDG-PET scan, with no evidence of malignancy identified. Patient A, a 35-year-old female, had persistent thymic prominence on CT scan. Removal of the thymus did not result in significant fall in VGKC Ab titre in this patient. Histological examination showed thymic hyperplasia, and no evidence of thymoma.
All patients apart from Patient F initially received treatment with standard first line antiepileptic drugs (AEDs) for focal epilepsy with a partial reduction in seizure frequency observed. Patient F was tested for VGKC Ab at presentation, and was initiated on immunotherapy prior to commencing AEDs. AED therapy was subsequently used, but failed to produce complete seizure control. LGI1 -Negative
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LGI1 -Negative CASPR2 -Negative
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LGI1 -Negative CASPR2 -Negative All patients received immunotherapy with corticosteroids following the identification of VGKC Abs. Intravenous methylprednisolone was used initially in Patients A and C, and oral prednisolone in others. Patients A, B and D also received azathioprine. The dosing information for steroids and azathioprine is presented in Fig. 2 . Changes in VGKC Ab titre and seizure frequency during immunotherapy in each of the 6 patients is depicted in Fig. 2 . All patients showed marked improvement in seizure control, with three patients achieving seizure freedom. Patient F discontinued steroid therapy due to adverse effects, and suffered recurrence of seizures. There was however no consistent correlation between fall in VGKC Ab titres and improvement in seizure control.
Discussion
It is likely that autoimmune processes, specifically the generation of antibodies to neuronal surface antigens underlie some epilepsies. 6, [10] [11] [12] [13] 17 Voltage gated potassium channels are of interest in epilepsy, as they play an important role in regulating neuronal excitability. In this cohort of 144 adult patients with otherwise unexplained epilepsy, 6 (4.2%) had significant titres of VGKC Abs. Three previous studies have reported a prevalence of VGKC Ab in 6%, 5% and 11% respectively in cohorts of patients with epilepsy, but these authors included all patients with VGKC Ab titres >100 pM. 3, 6, 11 We have restricted our analysis to patients with titres >400 pM as lower titres can be present in up to 5% of adult controls, and does not reliably distinguish patients with neurological disorders. 7 The VGKC Ab positive patients in our cohort are a heterogeneous group, both serologically and clinically. Two patients had antibodies against specific neuronal surface targets (LGI1 and CASPR2) and one conforms to the recently described FBDS phenotype. The other patients had strongly positive VGKC Ab, but the specific antigenic target is unknown. One patient (B) had MRI changes consistent with LE yet lacked the typical clinical symptoms of amnesia, encephalopathy, behavioural change and temporal lobe seizures. In no patient was an underlying tumour discovered, and one patient had thymic hyperplasia. All our patients had improvement in seizure control with immunotherapy, although not all have been rendered seizure free. The antibody titres have also fallen, albeit not in a uniform way, across the group in response to immunotherapy. Despite this the overall favourable response to immunosuppression, in patients for whom AEDs alone were not achieving seizure freedom, supports the concept of immune mediated epilepsy in this group. Zuliani et al. have proposed criteria for diagnosis of neuronal surface antibody associated neurological syndromes (NSAS). 15 Although only one of our patients had evidence of CNS inflammation on imaging, the presence of VGKC Ab (an NSAb) and the good response to immunotherapy indicates that VGKC Ab associated epilepsy is a NSAS. It could be postulated that VGKC Abs are not primarily pathogenic, but occur as a secondary response to neuronal damage relating to seizures. However, the good clinical response to immunotherapy, which, in Patients B, C, E and less so in D, mirrored the fall in antibody titre indicates a pathogenic role for VGKC Ab in our patients. Another possibility is that VGKC Ab associated epilepsy is part of a spectrum of VGKC Ab mediated CNS disorders, which includes LE and Morvans syndrome, or the acute phase of an autoimmune illness which can evolve into chronic temporal lobe epilepsy, as has been suggested by Bien et al.
14 None of our patients however had the full clinical syndrome of LE, or hyponatraemia, which has been described in patients with VGKC Ab associated LE in 59-80% of cases 5, 8 . In this regard, our patients bear similarity to patients with FBDS, none of whom had hyponatraemia in a series of 13 cases. 10 Additionally, in most cases of VGKC Ab mediated LE, VGKC Ab is directed against the LGI1 subunit. 8, 16 LGI1 subunit antibodies were found in only one of our patients, CASPR2 subunit antibodies were found in one other and the other 4 patients negative for both. In the study by Brenner et al., only one of 20 patients with epilepsy testing positive for VGKC Ab had antibodies to LGI1, and no patient had CASPR2 antibodies. It is likely therefore that the VGKC Abs in patients with epilepsy is directed against another component of the VGKC complex. This suggests that VGKC Ab associated epilepsy may be a distinct clinicoimmunological syndrome from VGKC Ab mediated LE. This is a retrospective review of clinical cases and therefore there are limitations to the conclusions that can be drawn. Not all patients had lumbar punctures and detailed neuropsychology was not carried out at the time of presentation in all cases. The antibody testing was carried out in a clinical and pragmatic way, with sera being 'screened' initially for the presence of VGKC Ab and only the strongly positive cases further tested for LGI1 and CASPR2 antibodies. Our testing paradigm would not have identified patients with LGI1 and CASPR2 antibodies without being strongly positive for VGKC Ab. However, our results add to a growing body of evidence pointing to antibodies to neuronal surface antigens underlying some epilepsies, and indicates the need for further studies. Efforts should focus on identifying the antigenic target in patients with VGKC Ab associated epilepsy, but test negative for
LGI1 and CASPR2 antibodies. While corticosteroid treatment appeared to benefit our patients, the most appropriate form and duration of immunotherapy for patients with epilepsy and VGKC Abs remain to be identified.
